Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro

Fig. 4

Tissue factor activity in A-375 and SK-MEL-28 cells after 48 h of treatment with Dabrafenib, Trametinib or DMSO as control. TF activity is expressed as U/mg of protein and it has been measured by a clotting assay conducted on monodisperse cell suspension as described in “Methods” section. Data are from a representative experiment of three and are reported as mean ± standard deviation of four replicates. Statistical analysis: 1 way-ANOVA and Tukey’s multiple comparisons test: §p < 0.01, *p < 0.0001 vs. DMSO

Back to article page